Inhibitory effect of 2'-fluoro-5-methyl-β-L-arabinofuranosyl uracil on duck hepatitis B virus replication

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 369-376

  Aguesse Germon, Stéphanie ^a   Liu, Shwu Huey ^b   Chevallier, Michèle ^c   Pichoud, Christian ^a   Jamard, Catherine ^a   Borel, Christelle ^a   Chu, Chung K ^d   Trépo, Christian ^a   Cheng, Yung Chi ^b   Zoulim, Fabien ^a  

^a INSERM   (France)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Lab Pasteur Merieux Connaught   (France)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYCYTIDINE DERIVATIVE; 2',3' DIDEOXYTHYMIDINE TRIPHOSPHATE; CIRCULAR DNA; CLEVUDINE; PRIMER DNA; RNA DIRECTED DNA POLYMERASE; VIRUS DNA; ZALCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUCK; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIREMIA; VIRION; VIRUS INHIBITION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA, VIRAL; DUCKS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; LIVER; VIRUS REPLICATION;

EID: 0031940764     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bartholomew, M., R. Jansen, L. Jeffers, K. Reddy, L. Johnson, H. Bunzendahl, L. Condreay, A. Tzakis, A. Schiff, and N. Brown. 1997. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
2. Bridges, E., and Y. C. Cheng. 1995. Use of novel β-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Prog. Liver Dis. 13:231-245.
3. Chassot, S., V. Lambert, A. Kay, C. Godinot, C. Trépo, and L. Cova. 1994. Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning. Virology 200:72-78.
4. Chen, C., and Y. C. Cheng. 1989. Delayed cytoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
5. Cheng, Y.-C. Unpublished data.
6. Chevallier, M., S. Guerret, P. Chossegros, F. Gérard, and J. A. Grimaud. 1994. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 2:349-355.
7. Chu, C., T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S. Pai, G. Yao, J. P. Sommadossi, and Y. C. Cheng. 1995. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39:979-981.
8. Cui, L., S. Yoon, R. Schinazi, and J. P. Sommadossi. 1995. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human. J. Clin. Invest. 95:555-563.
9. Dandri, M., P. Schirmacher, and C. Rogler. 1996. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J. Virol. 70:5246-5254.
10. Dannaoui, E., C. Trépo, and F. Zoulim. 1997. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
11. Fourel, I., J. Cullen, J. Saputelli, C. Aldrich, P. Schaffer, D. Averett, J. Pugh, and W. Mason. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321-8330.
12. Fourel, I., O. Hantz, K. Watanabe, C. Jacquet, B. Chomel, J. Fox, and C. Trépo. 1990. Inhibitory effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 34:473-475.
13. Fourel, I., J. S. Li, O. Hantz, C. Jacquet, J. J. Fox, and C. Trépo. 1992. Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and in liver of chronically infected ducks. J. Med. Virol. 37:122-126.
14. Fourel, I., J. Saputelli, P. Schaffer, and W. Mason. 1994. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 68:1059-1065.
15. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
16. Jilbert, A. Personal communications.
17. Jilbert, A. R., T. T. Wu, J. M. England, P. De La M. Hall, N. Z. Carp, A. P. O'Connell, and W. S. Mason. 1992. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
18. Lambert, V., S. Chassot, A. Kay, C. Trépo, and L. Cova. 1991. In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology 185:446-450.
19. Lanford, R., L. Notvall, and B. Beames. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
20. Lee, W. 1995. Drug-induced hepatotoxicity. N. Engl. J. Med. 333:1118-1127.
21. Lewis, W., E. Levine, B. Griniuvene, K. Tankersley, J. Colacino, J. P. Sommadossi, K. Watanabe, and F. Perrino. 1996. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc. Natl. Acad. Sci. USA 93:3592-3597.
22. Lin, E., C. Luscombe, Y. Wang, T. Shaw, and S. Locarnini. 1996. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 40:413-418.
23. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
24. Mason, W., J. Cullen, J. Saputelli, T. Wu, C. Liu, W. London, E. Lustbader, P. Schaffer, A. O'Connell, I. Fourel, C. Aldrich, and A. Jilbert. 1994. Characterization of the antiviral activity of 2′-carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 19:398-411.
25. Mason, W. S., G. Seal, and J. Summers. 1980. Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J. Virol. 36:829-836.
26. Mason, W. S., and J. M. Taylor. 1989. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology 9:635-645.
27. McKenzie, R., M. Fried, R. Sallie, H. Conjeevaram, A. Di Bisceglie, Y. Park, B. Savarese, D. Kleiner, M. Toskos, C. Luciano, T. Pruett, J. Stotka, S. Strau, and J. Hoofnagle. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333:1099-1105.
28. Nair, V., and T. Jahnke. 1995. Antiviral activities of isomeric dideoxynucleosides of D- and L-related stereochemistry. Antimicrob. Agents Chemother. 39:1017-1029.
29. Pai, S., S. Liu, Y. Zhu, C. K. Chu, and Y. C. Cheng. 1996. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40:380-386.
30. Parker, W., and Y. C. Cheng. 1994. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6:57-61.
31. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38:719-723.
32. Staschke, K., and J. Colacino. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 68:8265-8269.
33. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
34. Tennant, B., J. Jacob, L. Graham, S. Peek, B. Korba, J. Gerin, J. Witcher, F. Boudinot, J. Du, and C. K. Chu. 1997. Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in the woodchuck model of hepatitis B virus (HBV) infection. Antivir. Res. 34:52 (abstr. 36).
35. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. Tyrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:714-717.
36. Tuttleman, J. S., J. C. Pugh, and J. W. Summers. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
37. Wang, G. H., and C. Seeger. 1992. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell 71:633-640.
38. Wang, J., and S. Eriksson. 1996. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob. Agents Chemother. 40:1555-1557.
39. Wu, T.-T., L. Coates, C. E. Aldrich, J. Summers, and W. S. Mason. 1990. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175:255-261.
40. Zoulim, F., E. Dannaoui, C. Borel, O. Hantz, T. Lin, S. Liu, C. Trépo, and Y. C. Cheng. 1996. 2′,3′-Dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:448-453.
41. Zoulim, F., and C. Seeger. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.
42. Zoulim, F., and C. Trépo. 1994. Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications. J. Hepatol. 21:142-144.